Fleming Asset Management will roll out its Luxembourg Global Life Sciences Fund on 14 April. The fun...
Fleming Asset Management will roll out its Luxembourg Global Life Sciences Fund on 14 April.
The fund will be managed by Christopher Jones, who also runs Fleming Select American Smaller Companies, which has a biotechnology bias. He will be assisted by three analysts: John Regan, Marjan Daeipour and Craig Leighton. Jonathan Price, product manager for Fleming Asset Management in the US, said: "The project to map the human genome will be completed within six months, much earlier than was anticipated. There will be a massive revolution in healthcare as drugs will be able to target specific diseases or be tailored for specific people, such as a white male with diabetes."
Price said that there are between 100,000 and 200,000 genes in the human body, but 90% of existing drugs react with only 500 genes.
The Fleming fund will be looking to invest in companies at the forefront of this technology, which can supply and enable its use. Inevitably, smaller companies are involved. If a small company discovers a gene-based drug, it will be able to licence future use to bigger companies and charge a royalty, Flemings said.
First mentioned in Cridland Report
Second acquisition of 2019
Guy Opperman has rejected calls to speed up changes to auto-enrolment (AE) despite increasing pressure to boost contribution rates and overall savings pots.
Four key areas to focus on
And 94% for critical illness